Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies

Ruofan Li1,8, Michael Mor2,8, Bingting Ma1,8, Alex E. Clark3, Joel Alter4, Michal Werbner5, Jamie Casey Lee6, Sandra L. Leibel6,7, Aaron F. Carlin3, Moshe Dessau4, Meital Gal-Tanamy5, Ben A. Croker6, Ye Xiang1✉, & Natalia T. Freund2✉

As new variants of SARS-CoV-2 continue to emerge, it is important to assess the cross-neutralizing capabilities of antibodies naturally elicited during wild type SARS-CoV-2 infection. In the present study, we evaluate the activity of nine anti-SARS-CoV-2 monoclonal antibodies (mAbs), previously isolated from convalescent donors infected with the Wuhan-Hu-1 strain, against the SARS-CoV-2 variants of concern (VOC) Alpha, Beta, Gamma, Delta and Omicron. By testing an array of mutated spike receptor binding domain (RBD) proteins, cell-expressed spike proteins from VOCs, and neutralization of SARS-CoV-2 VOCs as pseudoviruses, or as the authentic viruses in culture, we show that mAbs directed against the ACE2 binding site (ACE2bs) are more sensitive to viral evolution compared to anti-RBD non-ACE2bs mAbs, two of which retain their potency against all VOCs tested. At the second part of our study, we reveal the neutralization mechanisms at high molecular resolution of two anti-SARS-CoV-2 neutralizing mAbs by structural characterization. We solve the structures of the Delta-neutralizing ACE2bs mAb TAU-2303 with the SARS-CoV-2 spike trimer and RBD at 4.5 Å and 2.42 Å resolutions, respectively, revealing a similar mode of binding to that between the RBD and ACE2. Furthermore, we provide five additional structures (at resolutions of 4.7 Å, 7.3 Å, 6.4 Å, 3.3 Å, and 6.1 Å) of a second antibody, TAU-2212, complexed with the SARS-CoV-2 spike trimer. TAU-2212 binds an exclusively quaternary epitope, and exhibits a unique, flexible mode of neutralization that involves transitioning between five different conformations, with both arms of the antibody recruited for cross linking intra- and inter-spike RBD subunits. Our study provides additional mechanistic understanding about how antibodies neutralize SARS-CoV-2 and its emerging variants and provides insights on the likelihood of reinfections.
Within 2 years of the emergence of SARS Coronavirus 2 (SARS-CoV-2) in Wuhan province, the original virus strain has been completely replaced by more transmissible variants, with Omicron emerging as the latest variant of concern (VOC). In view of the unexpectedly fast rates of viral evolution, it is important to estimate the degree to which neutralizing antibodies elicited naturally following infection with the original wild type strain (Wuhan-Hu-1), are cross reactive with circulating, present and future, VOCs. This is particularly relevant considering recent reports that vaccination provides considerably less protection against SARS-CoV-2 variants than against the original strain1–3.

The SARS-CoV-2 antibody response has been profiled at the sequence, structural, and mechanistic level by cloning and characterizing monoclonal antibodies (mAbs) from Wuhan-Hu-1-infected convalescent donors4–9. However, with the emergence of variants, many of these mAbs, some of which have been approved for treatment of COVID-19 patients10–12, have become ineffective13–15, while others retain activity16. This indicates that some antibodies elicited by infection are more variation-sensitive than others, and that antibody breadth of specificity, and not only potency, should be considered. A finer resolution investigation of the mechanistic and functional basis of SARS-CoV-2 antibody neutralization is therefore needed to predict the effect viral modifications will have on antibody activity, and to estimate the degree of protection from SARS-CoV-2 reinfection and breakthrough infection. Moreover, studying the molecular recognition of naturally elicited neutralizing antibodies in the context of heterologous viruses can reveal sites with a lower tendency to variation.

We have previously identified a panel of neutralizing SARS-CoV-2 antibodies derived from two COVID-19 survivors who were infected in Israel in March 2020, likely with the Wuhan-Hu-1 strain9. Seven of these mAbs (TAU-1109, -1145, -2189, -2212, -2230, -2303, and -2310) exhibited potent SARS-CoV-2 neutralizing activity, while the activity of another two (TAU-1115 and TAU-2220) was less potent. All the mAbs, except one, bind soluble receptor binding domain (RBD) and spike with high affinity. The exception, TAU-2212, which is one of the most potent neutralizing mAbs, binds an unknown conformational surface, and binding can only be detected when the spike protein is expressed on viral particles or cells. While exhibiting neutralizing activity against the Wuhan-Hu-1 strain, the cross-reactivity of these mAbs with SARS-CoV-2 VOCs is unknown.

The present study was designed to investigate the breadth of specificity and structural basis of the neutralizing activity of our previously isolated mAbs, in the context of the emerging variants Alpha (B.1.1.7)17, Beta (B.1.351)18, Gamma (P.1 or B.1.1.28.1)19, Delta (B.1.617.2)20,21 and Omicron (B.1.1.529)22. The results indicate that the most potent mAbs in our panel are predominantly directed against the ACE2bs supersite and are also the ones most sensitive to viral diversification. To understand the basis of neutralization and escape at the atomic level, we used cryo electron microscopy (cryoEM) and X-ray crystallography to determine structures of the two mAbs: TAU-2303 and TAU-2212. The results indicate that the interaction of TAU-2303 Fab and SARS-CoV-2 RBD resembles that of the ACE2 receptor with RBD in the “up” RBD conformation. In contrast, mAb TAU-2212 exhibits an unusual recognition flexibility type of binding involving five different possible conformations, with 1–3 Fab’s binding to one spike trimer, or cross-linking adjacent trimers by forming both intra- and inter-spike contacts, and favoring RBD in the “down” position. Our study provides important mechanistic and structural insights about neutralization of SARS-CoV-2 VOCs by natural antibodies, together with molecular modeling predictions of mAb interactions with the Omicron variant.

Results
Antibodies binding at the ACE2bs are more sensitive to viral mutations. The results of our previous study indicated that mAbs TAU-1145, -2189, -2230, and -2303 compete with ACE2, and are therefore defined as ACE2bs mAbs, while mAbs TAU-1109, -1115, -2220, -2310 do not compete with ACE2, and are therefore defined as non-ACE2bs9. The last neutralizing mAb, TAU-2212, does not bind soluble SARS-CoV-2 antigens (RBD or spike) by ELISA and recognizes an unknown epitope9. To examine the recognition of the RBDs from SARS-CoV-2 VOCs by our previously isolated mAbs, we generated soluble RBD proteins containing the mutations identified in the Alpha, Beta, Gamma, Delta and Omicron strains (Supplementary Table 1) and tested the binding by the eight mAbs that originally exhibited strong binding to the wild type strain RBD9. With the exception of Alpha, we observed a reduction in binding efficiency of the ACE2bs mAbs to all the VOCs (Fig. 1a and Supplementary Fig. 1). This was most significant for Beta, Delta and Omicron RBDs but was also present, albeit to a lesser extent, for the Gamma variant. Amongst the ACE2bs mAbs, only TAU-2303 maintained its original activity against the Delta strain. TAU-2212 does not bind soluble RBD and could not be evaluated using this assay9. To investigate the individual contribution of each mutation, we generated RBDs harboring single or double amino acid substitutions corresponding to variants Beta, Gamma and Delta. Of the eight single-mutated RBDs tested, both the L452R (present in the Delta VOC23) and E484K (present in both the Beta and Gamma VOCs24) substitutions had a major impact on antibody binding (Fig. 1b, d and Supplementary Fig. 1). Other single substitutions, however, had no effect on mAb binding. Furthermore, RBDs containing single mutations N439K25, Y453F26,27 and A475V28, which have been reported in some circulating SARS-CoV-2 strains, were bound by all mAbs as strongly as the original wild type RBD. Interestingly, the binding of mAb TAU-2303 to the double mutant K417N/N501Y was reduced although each of the two single mutants separately had no effect (Fig. 1c, d and Supplementary Fig. 1). Overall, we conclude that ACE2bs mAbs are more sensitive to mutations in the RBDs than non-ACE2bs mAbs.

Mutations outside the RBD may also affect the activity of RBD-binding mAbs by altering the conformational organization of the trimer9. Therefore, we next expressed the full-length spike protein of wild type, Alpha, Beta, and Delta variants (Supplementary Table 1) on Expi293F cells, and assayed the ability of each mAb to inhibit binding of soluble human ACE2 (hACE2) by flow cytometry. The Gamma full-length spike protein was not produced since the RBD of this variant exhibited similar activity to the Beta RBD. As expected, most of the ACE2bs mAbs effectively inhibited the ACE2:spike (wild type) and ACE2:spikeAlpha interactions, but not those between the ACE2:spikeBeta and ACE2:spikeDelta. The mAb TAU-2212, which can be tested in this assay, demonstrated 25–40% ACE2:spike inhibition when tested against the wild type, Alpha and Delta strains, but had no activity against Beta (Fig. 2a, b and Supplementary Fig. 2). In fact, none of the ACE2bs mAbs retained their original potency against the Beta variant, and, in accordance with the ELISA data, only mAb TAU-2303 retained its full activity against the Delta variant. As expected, no effect was observed for mAbs TAU-1109, -2310, -1115 and -2220, as the neutralization does not act through receptor blocking.
Fig. 1 Antibody binding to the RBD of wild type and SARS-CoV-2 VOCs by ELISA. ACE2bs or non-ACE2bs antibodies are indicated to the left of each panel, a–d. For panels a–c, each graph represents antibody binding to wild type or VOC (a), single (b) or double (c) mutant RBD. AUC was calculated by GraphPad Prism. The raw OD_{650} values, as well as isotype control, are presented in Supplementary Fig. 1. Each experiment was repeated at least three times (n ≥ 3). d Summary of the antibody binding affinity to each RBD generated in this study. Green color indicates binding affinity of >75%, orange of 25–75%, and yellow of <25% as compared to wild type RBD. The VOCs harboring each mutation are indicated.
**SARS-CoV-2 VOCs are resistant to most ACE2bs mAbs.** We next evaluated the ability of the mAbs to prevent infection. We employed a pseudo-viral neutralization assay and infection of Vero-TMPRSS2 cells with authentic SARS-CoV-2 to test the activity of the nine mAbs against SARS-CoV-2 wild type and VOCs (Fig. 3). In accordance with the ELISA and flow cytometry results, the Alpha VOC behaved similarly to the wild type strain, while the Beta and Omicron variants were the most resistant, followed by Gamma and Delta. In agreement with the ELISA and flow cytometry results, mAb TAU-2303 was the only ACE2bs mAb that was able to neutralize the Delta VOC, with improved potency compared to the wild type strain (Fig. 3a). The non-ACE2bs mAbs TAU-1109 and -2310 retained their efficacy against all tested VOCs, with TAU-2310 exhibiting improved activity against the Delta variant compared to the wild type (Fig. 3a, b). These results indicate a crucial support role for non-ACE2bs mAbs in the presence of viral mutations that prevent neutralization by ACE2bs mAbs. Additionally, the improved

---

**Fig. 2 Antibody inhibition of soluble human ACE2 binding to cell-expressed spike.** a Flow cytometry plots demonstrating the effectiveness of each mAb when interfering with spike:ACE2 binding (see Supplementary Fig. 2 for more details). Expi293F cells were transfected to express the wild type, Alpha, Beta, or Delta spike, and were incubated with each antibody, before being stained with human ACE2 (hACE2) conjugated to APC. Unlabeled hACE2 (“cold” hACE2) was used as a positive control, and mGO5366 antibody as an isotype control. Within each plot, the blue histogram indicates treated cells, while the red indicates untreated. Each experiment was repeated at least three times (n ≥ 3). b Normalized percent of spike:ACE2 inhibition, calculated by measuring the percent of hACE2-APC positive cells in the presence of each mAb, dividing it by the percent of hACE2-APC positive cells (hACE2 only), and normalizing to 100%. c Pie charts indicating the frequency of spike:ACE2 inhibiting mAbs for wild type and VOCs.
Fig. 3 Antibody neutralization of wild type and VOCs. 

a Antibody neutralization curves of wild type, Alpha, Beta, and Delta VOC pseudo-typed GFP reporter viral particles. For every mAb, each curve represents inhibition of one VOC as indicated. Antibodies were pre-incubated with viral particles at 8 consecutive 3-fold dilutions starting at 10 μg/mL of antibody. Fluorescence of infected cells was read 72 h post infection. Inhibition percentage was calculated by normalizing to untreated cells. Each experiment was done in triplicate (n = 3). mGO53 was used as an isotype control. Error bars indicate SD.

b Infection of Vero-TMPRSS2 cells by wild type (n = 4), Alpha (n = 2), Beta (n = 4), Gamma (n = 4), Delta and Omicron (n = 6) with authentic SARS-CoV-2 and overlayed with carboxymethylcellulose. Values are expressed as the infected surface area of cells and normalized to infected cells without mAb. Viral particles were pre-incubated with 100 μg/mL of antibody for 1 h before addition to the cells. Infected cells were identified at 24 h post infection using SARS-CoV-2 nucleocapsid antibody after cell fixation and permeabilization. Infected cells were quantified using Incucyte S3. mGO53 serves as an isotype control. Error bars indicate SD.
activity of TAU-2310 and TAU-2303 mAbs demonstrates how genetic variation in a SARS-CoV-2 VOC can increase neutralization for some classes of mAbs.

**Structural basis of neutralization of the ACE2bs mAb TAU-2303.** Viral evolution appears to be primarily focused on the ACE2bs supersite, consistent with the overall superior potency of receptor blocking mAbs to inhibit SARS-CoV-2. We decided to focus on mAb TAU-2303, which is the only ACE2bs mAb that is active against the Delta VOC, and mAb TAU-2212 that blocks receptor binding through recognition of a conformational surface, and further investigate the structural basis of neutralization for these two mAbs. We first determined the cryoEM structure of the fragment of antigen-binding (Fab) of TAU-2303 (Fab2303) in complex with the ecto SARS-CoV-2 spike trimer, at a resolution of 4.5 Å (Fig. 4a). The cryoEM structure revealed that one Fab2303 molecule binds one spike trimer on the protruding "up" facing RBD. Therefore, mAb TAU-2303 can be categorized as a CoV2130-type, that belongs to Class 1 RBD binding mAbs, and binds only one RBD subunit amongst the three available subunits of the trimer (Fig. 4a). We also crystallized Fab2303 in complex with SARS-CoV-2 RBD and analyzed the structure at a resolution of 2.4 Å (Fig. 4b Table 1). The results from both the crystal and cryoEM structures indicated that Fab2303-RBD complex has a large buried surface of 1185 Å², with the majority of the contact surface (64%) derived from the heavy chain of Fab2303, and only 36% from the light chain. A total of 29 RBD residues in the crystal structure have direct close contacts with Fab2303 (Supplementary Table 2). Consistent with the contact surface analysis, 19 of these residues are from the heavy chain (HC), while 10 are from the light chain (LC) of TAU-2303. The contact residues mediate the formation of 23 hydrogen bonds (Supplementary Table 2). These include five hydrogen bonds RBD-D420OD2 – Fab2303-HC-SS6OG, RBD-Y473OH – Fab2303-HC-S31O, RBD-T415OG1 – Fab2303-HC-Y52O, RBD-L455O – Fab2303-HC-Y33OH and RBD-Q493NE2 – Fab2303-HC-Y102OH with distances of below 2.7 Å (Supplementary Table 2). In accordance with the biochemistry and in vitro cell assays, 14 (K417, T453, L455, A475, F486, N487, Y489, Q493, G496, Q498, T500, N501, G502, and Y505) of the 29 contacts between Fab2303 and RBD are also involved in binding the ACE2 receptor, thus confirming that TAU-2303 neutralizes the virus by blocking receptor binding (Figs. 1–3, 4b and Supplementary Figs. 1,2). The angle of approach through which Fab2303 binds RBD is 25° relative to that of Ace2 (Fig. 4b). Further comparisons revealed that the binding mode of mAb TAU-2303 is similar to that of other Class 1 neutralizing antibodies that target RBD (Supplementary Fig. 3a, b)30–32.

The ELISA results indicated a reduction in TAU-2303 binding to RBD with the double mutations K417N/N501Y, but not to K417T/N501Y, or any of the single mutations K417N, K417T, or N501Y (Fig. 1 and Supplementary Fig. 1). This agrees with the crystal structure findings that residues K417 and N501 are both in direct contact with TAU-2303. Position 417 is particularly critical for TAU-2303 recognition, as Fab2303-HC-Y52OH forms hydrogen bonds both with the main chain atom N and the side chain atom NH of RBD-K417 (Fig. 4c, d and Supplementary Table 2). Modeling revealed that when lysine in position 417 is replaced with threonine, both the main chain and side chain hydrogen bonds could be retained (Fig. 4d). Moreover, it becomes possible to establish a new hydrogen bond between the OH atom of the threonine and the OH atom Fab2303-HC-Y33, thus decreasing the total binding energy calculated with PISA35 from -9.7 kJ/mol to -9.9 kJ/mol. In contrast, replacing lysine in position 417 by asparagine, increases the length of the hydrogen bonds between the side chain polar atoms ND2H or OD1 with Fab2303-HC-Y33 and Fab2303-HC-Y52, which decreases the favorability of the interaction, as indicated by the increase of the calculated binding energy from -9.7 kJ/mol to -9.5 kJ/mol (Fig. 4d). The asparagine in position 501 has a relatively large number of contacts with Fab2303. The N501 side chain forms two hydrogen bonds with main chain and side chain atoms of Fab2303-LC-S30 (Fig. 4c). While these hydrogen bonds would be completely disrupted by replacing asparagine with tyrosine, our modeling data suggest that new Van der Waals interactions could be formed with tyrosine in this position (Fig. 4d). Since these proposed Van der Waals interactions would not be able to fully compensate for the lost hydrogen bonds, mutant N501Y is predicted to have a slightly lower binding affinity to Fab2303, as is confirmed by affinity measurements by Surface Plasmon Resonance (SPR) (Supplementary Fig. 3c, d). Interestingly, although glutamate in position 484 was shown to be central to viral escape from neutralizing antibodies34–36, our structural analysis indicates that E484 does not make direct interactions with Fab2303. This point was further validated by further examination of the RBD and Fab2303 interface, revealed that E484 interacts with Fab2303-HC-Y102 through a water molecule (Fig. 4d). The observation that solvent-mediated interactions are usually weaker than direct contacts, is consistent with the results of our functional studies that, in contrast to the other ACE2bs mAbs, the single E484K mutation had no significant impact on TAU-2303 binding (Fig. 1 and Supplementary Fig. 1). The mutations T487K and L452R of RBD Delta are located outside the binding epitope of Fab2303, which, thus explains how TAU-2303 can still bind with high affinity and neutralize the Delta VOC (Fig. 4e and Supplementary Fig. 3c, d). The structure and modeling data explains why TAU-2303 can bind equally well to an RBD molecule with a single mutation, such as K417N, E484K, and N501Y, but not to an RBD mutant with all three mutations, with the greater cumulative loss of binding energy. Our structural data combining the biochemistry and neutralization results, suggest that the combination of RBD mutations may play a key role in conferring SARS-CoV-2 resistance. Significantly, the Omicron variant, has mutations in seven residues within the binding epitope of Fab2303, including four key contacting residues K417, Q493, Q498, and Y505, providing the structural explanation to the lack of neutralization of Omicron by TAU-2303 (Figs. 3 and 4e).

mAb TAU-2212 blocks ACE2 binding through conformational dynamics. TAU-2212 is one of the most potent mAbs in our panel, and while not being able to bind soluble RBD by ELISA, it inhibits ACE2 binding as measured by flow cytometry, suggesting that receptor binding is blocked through a different mechanism to that employed by TAU-2303. To investigate the neutralization mechanism of TAU-2212, we prepared Fab2212 by cleaving mAb TAU-2212 with papain. The purified Fab2212 was crystallized and the crystal was diffractioned to 2.7 Å. Data analysis revealed that the crystal belongs to the space group P61, with cell dimensions a = 75.98 Å, b = 75.98 Å, and c = 348.14 Å (Table 1), and with two molecules in the asymmetric unit. The structure was determined by molecular replacement and was refined to a final R/ Rfree of 0.202/0.246. The final model of Fab2212 contains 419 residues, while residues 141–151 and 197–204 of the heavy chain are not visible in the map (Fig. 5a). No significant differences were observed between the two molecules in the asymmetric unit (a calculated R.M.S.D. of 0.77 Å between the aligned Ca atoms, Supplementary Fig. 4). Fab2212 is not able to form a stable complex with the prefusion stabilized SARS-CoV-2 spike ectodomain (Supplementary Fig. 5a), but interacts with spike trimer on the cell surface9. With the supposition that TAU-2212 binds a
specific conformation of the prefusion spike trimer that is not stable when coated on ELISA plates, we used TAU-2212-protein A coated beads to pull down spike trimers, which were then subjected to cryoEM structural analysis. CryoEM 3-dimensional (3D) classification of the particles revealed that TAU-2212 binds the spike trimer in five distinct conformations (1–5), with 20339, 15868, 14193, 72056, and 39788 particles, respectively (Supplementary Fig. 6 and Table 2). In all five conformations, only the Fab portion of mAb TAU-2212 is visible, while the highly flexible Fc region is not seen in the reconstructed maps. Conformations 1, 3 and 4 are composed of two, three and three bound Fab, respectively, with all the RBDs in the “down” position. In
Fig. 4 Structural analysis of Fab2303 in complex with the SARS-CoV-2 spike trimer and RBD. a Ribbon diagrams showing the cryoEM structure of the SARS-CoV-2 spike trimer in complex with one TAU-2303 Fab (Fab2303). The “up” RBD protomer of the spike is colored blue. The other two protomers are colored salmon. The heavy chain of Fab2303 is colored pink and the light chain is colored cyan. b Left: ribbon diagrams showing the Fab2303-RBD crystal structure superimposed onto the ACE2-RBD crystal structure (PDB: 6M01). The RBD and Fab2303 are colored as in a. ACE2 is colored green. The solid and dashed lines in red indicate the long axes of ACE2 and Fab2303, respectively. Right: the paratope and epitope of Fab2303 shown as rendered surface representations. The paratope on Fab2303 and epitope on RBD are colored yellow. Red lines indicate the footprint of ACE2. c Detailed interactions between Fab2303 and SARS-CoV-2 RBD. HCDR and LCDR stand for complementarity-determining region (CDR) of the heavy and the light chain, respectively. LFR mutants were modeled in COOT53 by using the single mutate function, in which only the side chains of the mutated residues were changed. Most possible side chain conformations of the mutated residues were generated and selected from the rotamer library of COOT and according to the binding energy calculated with PISA. The heavy chain of Fab2303 is colored pink and the light chain is colored cyan. The RBD and Fab2303 are colored as in a, with the mutated RBD residues in green. d Surface mapping of key mutations in different variants and the positions of the mutated sites relative to the binding epitopes recognized by TAU-2303. The binding epitopes of TAU-2303 are colored yellow. The mutation sites within or outside the binding epitope of TAU-2303 are colored red and green, respectively.

| Table 1 X-ray Data collection and refinement statistics for RBD–Fab2303 complex and Fab2212. |
|---------------------------------------------------------------|
| **Data collection**                                           | **Fab2303** | **Fab2212** |
| Space group                                                 | C 2 2 2 1   | P 6 3     |
| Cell dimensions                                             | 85.13, 149.98, 144.79 | 75.98, 75.98, 348.14 |
| α, β, γ (°)                                                  | 90, 90, 90   | 90, 90, 120 |
| Resolution (Å)                                              | 20.09–2.42   | 29.75–2.71 |
| R<sub>merge</sub>                                           | 0.19 (0.751) | 0.145 (0.924) |
| Completeness (%)                                             | 99.44 (95.98) | 99.68 (97.60) |
| Redundancy                                                   | 12.1 (10.2)  | 8.7 (7.1) |
| **Refinement**                                               |              |            |
| Resolution (Å)                                              | 20.09–2.42   | 29.75–2.71 |
| No. reflections                                             | 35382 (3389) | 30759 (3006) |
| R<sub>work</sub>/R<sub>free</sub>                           | 0.1821/0.2201 | 0.2015/0.2462 |
| No. atoms                                                    | 5171          | 6293       |
| Protein                                                     | 4821          | 6293       |
| Ligand/ion                                                  | 14            | -          |
| Water                                                       | 336           | 333        |
| B-factors(Å<sup>2</sup>)                                    | 47.08         | 93.79      |
| Protein                                                    | 46.99         | 95.59      |
| Ligand/ion                                                  | 72.98         | -          |
| Water                                                       | 47.24         | 59.67      |
| **R.m.s. deviations**                                        |              |            |
| Bond lengths (Å)                                            | 0.004         | 0.008      |
| Bond angles (°)                                             | 0.72          | 0.97       |

*Values in parentheses are for highest-resolution shell.

Conformation 4 of the TAU-2212:spike complex has all the RBDs in the “down” position with three TAU-2212 moieties binding near the junctions between the RBDs. Each Fab2212 binds and crosslinks two adjacent “down” RBDs (RBD1 and 2) with a buried surface of 823 Å<sup>2</sup> on RBD1 and 298 Å<sup>2</sup> on RBD2 (Fig. 5b). Comparing the structures of the TAU-2212-bound and free spikes revealed that TAU-2212 binding induces conformational changes in the RBDs, producing an anti-clockwise rotation of 4.1° towards the symmetry axis, and resulting in a more compact RBD head structure after TAU-2212 binding (Supplementary Fig. 9a). The conformational changes in the RBDs bring residues at the interfaces closer and may increase the Van der Waals interactions between the RBDs. However, no additional contacts are observed between the “down” RBDs. In addition, the RBD loops 454–462 and 468–489 that are disordered in free spikes are well ordered in the complex structure by forming three hydrogen bonds with the bound TAU-2212 (Supplementary Fig. 9b and Supplementary Table 3). These loops are also ordered and visible upon ACE2 binding. These data suggest that TAU-2212 acts by binding and stabilizing the SARS-CoV-2 spike trimer in a “down” orientation and prevents conformational change to “up” RBD which is required for spike:ACE2 interactions.

Most of the epitope recognized by mAb TAU-2212 is on one of the two RBDs (RBD1), and the interactions are predominantly through the heavy chain, especially the CDR3 loop of the heavy chain (HCDR3), which is embedded within the interface of two RBDs. Two CDR loops of the light chain interact directly with two residues on RBD1 (485–486) and the ND2 loop of Fab2212-HC-Y93 (Fig. 5d). Overall, the interactions between the HCDR loops and RBD1 and RBD2 involve 57 residues, and 13 pairs of hydrogen bonds (Fig. 5d and Supplementary Table 3). These interactions include two hydrogen bonds formed by the OE2 group of E484<sub>RBD1</sub>, with the OH group of Fab2212-HC-Y33, and the ND2 group of Fab2212-HC-N52. The length of the hydrogen bond between the OE2 group of E484<sub>RBD</sub> and the OH group of Fab2212-HC-Y33 is 2.2 Å, suggesting that this hydrogen bond could be the main interaction at the contact interface. The E484K mutation completely disrupts the hydrogen bonds between the antibody and the RBD (Fig. 5e and Supplementary Fig. 5b), providing a structural explanation for the complete resistance of the Beta and Gamma VOCs to TAU-2212. Similarly, both the E484A and Q493R mutations present in the Omicron variant, are considered likely to disrupt the key hydrogen bonds and are therefore expected to affect TAU-2212 binding and reduce neutralization capacity (Fig. 5f). Substitution S373P is present in the new Omicron variant, also lies within the TAU-2212 interface. To test the effect of S373P mutation on TAU-2212
binding, we first introduced a S373G mutation to disrupt the hydrogen bond mediated by the hydroxyl group of serine 373. The results showed that the S373-mediated hydrogen bond did not affect the binding of TAU-2212 (Supplementary Fig. 5b). Next, we performed a pull down experiment to test the interaction between mutant S373P and TAU-2212 (Supplementary Fig. 5c). The results showed that TAU-2212 can still bind spike with the S373P mutation, which further supports that both the hydrogen bond and Van Der Waals force mediated by S373 side chain do not play a major role in TAU-2212 binding spike. Taking the effect of all the mutations together, it is therefore not surprising that TAU-2212 does not neutralize Omicron.
Fig. 5 Structural analysis of TAU-2212 in complex with the SARS-CoV-2 spike trimer. a Ribbon diagram showing the crystal structure of Fab2212. The heavy and light chains are colored pink and light green, respectively. The CDR loops are colored yellow. The missing residues 141-151 and 197-204 of the heavy chain are shown as pink dashed lines. b Surface diagrams showing the side (left) and the top open-up (right) views of the spike trimer with three bound Fabs of mAb TAU-2212. The RBDs of the spike trimer are colored blue and the Fab2212 heavy and light chains are colored as in a. The binding epitopes of the heavy and light chains around the junction of two RBDs are colored yellow and white, respectively. The mutation sites within or outside the RBDs), are positioned at a small bending configuration may not be favorable for TAU-2212 binding through which is likely to be in the RBD “up” conformations. Structural analysis of the bound Fabs indicated that the constant regions of the three bound Fabs in conformation 4 (three Fabs binding three “down” RBDs), are positioned at a small bending configuration. Therefore, the densities of bound Fabs2212 were considerably weaker in conformation 2 than in the other conformations, indicating that the “one up” - “two down” configuration may not be favorable for TAU-2212 binding (Fig. 5c). This possibility was also suggested by the pull-down results. To obtain the TAU-2212: spike complex, we applied more spike and a large portion of the spike protein was in the flowthrough which is likely to be in the RBD “up” conformations. Given the flexibility and dynamics of the interaction between TAU-2212 and the spike trimer, we examined binding of the Fab2212 variable regions to the adjacent RBDs in conformations 1–5. We noticed that the densities of bound Fabs2212 were considerably weaker in conformation 2 than in the other conformations, indicating that the “one up” - “two down” configuration may not be favorable for TAU-2212 binding through which is likely to be in the RBD “up” conformations. Structural analysis of the bound Fabs indicated that the constant regions of the three bound Fabs in conformation 4 (three Fabs binding three “down” RBDs), are positioned at a small bending configuration. Therefore, the densities of bound Fabs2212 were considerably weaker in conformation 2 than in the other conformations, indicating that the “one up” - “two down” configuration may not be favorable for TAU-2212 binding through which is likely to be in the RBD “up” conformations. Given the flexibility and dynamics of the interaction between TAU-2212 and the spike trimer, we examined binding of the Fab2212 variable regions to the adjacent RBDs in conformations 1–5. We noticed that the densities of bound Fabs2212 were considerably weaker in conformation 2 than in the other conformations, indicating that the “one up” - “two down” configuration may not be favorable for TAU-2212 binding through which is likely to be in the RBD “up” conformations. Structural analysis of the bound Fabs indicated that the constant regions of the three bound Fabs in conformation 4 (three Fabs binding three “down” RBDs), are positioned at a small bending configuration.

### Table 2 Cryo-EM data collection, refinement and validation statistics for spike–Fab2303 and spike–TAU-2212.

| Data collection and processing | S6P–Fab2303 | S2P–TAU-2212 |
|-------------------------------|-------------|--------------|
| Magnification                 | 22500       | 29000        |
| Voltage (kV)                  | 300         | 300          |
| Electron exposure (e⁻/Å²)     | 50          | 50           |
| Defocus range (µm)            | -1.5 to -2.8| -1.5 to -2.0 |
| Pixel size (Å)                | 1.25        | 0.97         |
| Symmetry imposed              | C1          | C1           |
| Initial particle images (no.) | 546293      | 275642       |
| Final particle images (no.)   | 38331       | 20339        |
| Map resolution (Å)            | 4.5         | 4.7          |
| FSC threshold                 | 0.143       | 0.143        |
| Map resolution range (Å)      | 4.5-30.0    | 4.7-30.0     |
| Refinement                    |             |              |
| Initial model used (PDB code) | 6XEY        |              |
| Model resolution (Å)          | 3.25        |              |
| FSC threshold                 | 0.143       |              |
| Model resolution range (Å)    | ∞–3.3       |              |
| Map sharpening B factor (Å²)  | -135.0      |              |
| Model composition             |             |              |
| Non-hydrogen atoms            | 33525       | 33525        |
| Protein residues              | 4284        | 4284         |
| Ligands                       | 33          | 33           |
| R.m.s. deviations             |             |              |
| Bond lengths (Å)              | 0.005       | 0.005        |
| Bond angles (°)               | 0.977       | 0.977        |
| Validation                    |             |              |
| MolProbity score              | 1.97        | 1.97         |
| Clashscore                    | 13.14       | 13.14        |
| Poor rotamers (%)             | 0.24        | 0.24         |
| Ramachandran plot             |             |              |
| Favored (%)                   | 95.14       | 95.14        |
| Allowed (%)                   | 4.86        | 4.86         |
| Disallowed (%)                | 0.00        | 0.00         |
angle (14.6°) relative to the variable regions that are aligned with the z axis (Fig. 5g). In addition, the three molecules are well separated (Fig. 5c) and the distances between the two C254s that form a disulphide bond and crosslink loops of the bound Fabs is ~21 Å (Supplementary Fig. 10), suggesting that the three bound Fabs belong to three different mAbs, rather than one mAb binding the trimer with both arms. The constant and variable domains of the bound Fabs in conformation 5 assume similar conformations as these in conformation 4, suggesting that the bound Fabs in conformation 5 belong to three different mAbs. In contrast to conformation 4, only two Fabs are present per trimer in conformation 1. The constant regions of the two bound Fabs in conformation 1 have a large bending angle (29.6°) and are joined at the distal end. In addition, the two C254s that crosslink loops of the bound Fabs have a reasonable distance of 4 Å (Supplementary Fig. 10), suggesting that in this case, the two bound Fabs belong to the same mAb (Fig. 5c and Supplementary Fig. 10). Notably, conformation 3 has the three bound Fabs in two distinct conformations. Two of the Fabs have similar bending angle as that observed in conformation 1, whereas one of the Fabs has a smaller bending angle as that observed in conformation 5, indicating that the binding of TAU-2212 in conformation 3 is in a mixed mode with two mAbs. Among these, one mAb contributes two Fabs, while one mAb provide only one Fab (Fig. 5c).

Structural analysis of the head-to-head spikes in conformation 5 reveal three mAbs that crosslink two spikes, with the two Fabs of each mAb in two linearly aligned 180° opposite positions (Fig. 5c and Supplementary Fig. 10c). As a result, the constant region of the bound Fab in conformation 5 has the smallest bending angle and is almost in a plane with the variable region. Given that most particles are in conformation 4, and no spike trimers were observed with all “down” RBDs and a single bound TAU-2212, we can deduce that binding of a single TAU-2212 mAb to the down RBD trimer triggers a conformational change that promotes additional Fab binding. With the binding of the first Fab, the second Fab of the bound mAb will be prone to binding the neighboring epitope. However, binding of both the Fabs in one mAb will cause bending in the bound Fabs as shown in conformation 2, which will reduce the stability of the interaction. Thus, the binding mode in conformation 1 could soon be replaced by the binding mode in conformation 4, whereas conformation 3 is likely an intermediate state between conformations 1 and 4. Taken together, mAb TAU-2212 adopts a unique binding mode to the spike. mAb TAU-2212 recognizes adjacent RBDs in a “down” conformation and crosslinks two spikes facing each other. However, a single Fab2212 barely binds the spike trimer, which is completely different from mAbs S2M11 and C144. Like mAb TAU-2212, S2M11 and C144 IgGs could also cause the head-to-head spike linkage. Our result indicates that natural IgG can also crosslink spike and promote virus particle aggregation as the “bispecific” nanobody Fu2 does,

Although the RBD conformation and epitopes are different in these complexes.

Discussion

Despite the relatively stable genome of SARS-CoV-2,

the continuing spread of the global pandemic has been accompanied by the emergence of new variants with improved transmissibility and mutations that contribute to immune evasion.

With enhanced affinity for human cells and alterations made to vulnerable residues within the spike, these new variants can jeopardize both mAb therapies and vaccines. The Alpha, Beta, Gamma, Delta, and Omicron VOCs are of particular interest as they completely replaced the original Wuhan-Hu-1 strain in subsequent “waves” of the pandemic. The first part of our study assessed the binding inhibition and neutralization of nine antibodies, previously isolated from Wuhan-Hu-1 SARS-CoV-2 infected individuals.

Consistent with other reports, we show that ACE2bs mAbs are more affected by viral mutations than mAbs that bind to regions outside the ACE2bs. While these are generally less potent against the original infecting virus, non-ACE2bs mAbs appear to have broader activity against emerging variants.

In the second part of our study, we investigated the mechanism of neutralization of two neutralizing receptor-blocking mAbs, TAU-2303 and TAU-2212, at the atomic level. The atomic structure of Fab2303:RBD confirmed that TAU-2303 binds a surface that is also bound by the ACE2 receptor, as we observed by functional assays. In contrast to other ACE2bs mAbs in our study, TAU-2303 remained active against the Delta VOC, likely due to the comparable modes of binding of ACE2 and TAU-2303 with respect to both epitope and angle of approach to the RBD. However, like the majority of mAbs that block receptor binding, TAU-2303 was less effective against the Beta and completely ineffective against Omicron variant. We next examined the atypical mAb, TAU-2212, which exhibits an unusual recognition flexibility type of binding involving five different conformations. TAU-2212 binds and crosslinks “down” RBDs by displaying exceptional conformational flexibility. According to the fitted structure of each conformation, the interfaces between the RBD and the variable region of the bound Fab2212 are consistent. We considered that the binding surface remains the same among the five conformations. The observation that TAU-2212 binds the spike complex in five different conformations suggests a flexibility of neutralization that is also achieved by stabilization of the spike trimer. The existence of a large number of TAU-2212 mAb crosslinked with head-to-head spikes suggests that TAU-2212 can potently crosslink and aggregate viral particles and thereby reduce the number of effective viral particles in the lung. Furthermore, the binding mode in conformations 1, 3, 4 or 5 would block any “up” conformation of the RBDs, thus, blocking receptor binding.

In these ways, TAU-2212 exhibits ACE2bs-like properties while utilizing a distinct mechanism of action. Alternative strategies that broaden neutralization capacity can be deduced from the previously reported antibodies S2M11 and C144 which crosslink two “down” RBDs and have a similar mode of binding to that of TAU-2212 (Supplementary Fig. 11). However, unlike TAU-2212, both S2M11 and C144 can bind the spike trimer with the Fab alone. Out of the three antibodies, S2M11 has the largest binding interface, while the binding interfaces of TAU-2212 and C144 are smaller and more similar (Supplementary Fig. 11). Like TAU-2212, S2M11 mAb promotes a compact RBD head, whereas C144 binding promotes the opposite effect by forcing the RBD head into an open conformation (Supplementary Fig. 11b). The larger binding interface of S2M11 encompasses E484 and L452 residues, and therefore is expected to lose efficacy against the Beta, Gamma and Delta variants, whereas TAU-2212 effectively neutralizes Delta (Fig. 3 and Supplementary Fig. 11). Like other mAbs in its class, TAU-2212 also exhibited a complete loss of activity against the Beta, Gamma and Omicron VOCs.

To summarize, our study provides functional and atomic-level structural data on the interactions between naturally elicited antibodies and SARS-CoV-2 variants. Both TAU-2303 and TAU-2212 are potently neutralizing but arise through different B cell developmental programs. Neutralization by TAU-2212 is successful for most of the mutations with the exception of E484K. We therefore conclude that combining mAbs that can bind E484K, such as TAU-1109, ~2303 or ~2310 with TAU-2212 may be useful for broad spectrum anti-viral neutralization.
Methods

Cloning and mutagenesis of variant SARS-CoV-2 RBDs. We used our previously described wild type plasmid12 as template for PCR mutagenesis designed to generate RBD constructs harboring single amino acid mutations. Pairs of overlap-lapping DNA primers containing one or two base pair substitutions flanked by 20 bases on each side were designed and synthesized by Syntezza-Israel. PCR reactions were performed using KAPA HiFi HotStart ReadyMix (Roche) DNA polymerase. Each PCR reaction contained 10 µL KAPA HiFi HotStart ReadyMix, 0.5 µM of each primer, and 1 ng template DNA, with the sample volume adjusted to 20 µL with DNaSe/RNase free water (Bio-Lab). The PCR conditions were as follows: 95 °C for 3 min, 16 cycles of 98 °C for 20 s, and 72 °C for 90 s. Double and triple amino acid mutants were generated similarly with appropriate templates and primers.

Expression and purification of soluble SARS-CoV-2 RBDs for ELISA. Each construct was used to transiently transfect Expi293F cells (Thermo Fisher) using the ExpiFectamine 293 Transfection Kit (Thermo Fisher). Seven days post transfection, the cell supernatant was collected, filtered (0.22 µm), and incubated with Ni²⁺-NTA agarose beads (GE Life Sciences) for 2 h at room temperature (RT). Proteins were eluted by 200 mM imidazole, buffer-exchanged to PBS ± x1, aliquoted, and stored at −80 °C.

ELISA. High-binding 96 well ELISA plates (Corning #9081) were coated with 1 µg/ml RBD in PBS ± x1 overnight at 4 °C. The following day, the coating was discarded, the wells were washed with “washing buffer” (PBS ± x1 and 0.05% Tween20) and blocked for 2 h at RT with 200 µL of “blocking buffer” (PBS ± x1, 3% BSA (MP Biomedical), 20 µL MEFA, and 0.05% Tween20 (Sigma)). Antibodies were added at a starting concentration of 4 µg/mL, and seven additional 4-fold dilutions in blocking buffer, and incubated for 1 h at RT. The plates were then washed 3 times with washing buffer before adding secondary, anti-human IgG (Jackson ImmunoResearch) antibody conjugated to horseradish peroxidase (HRP) diluted 1:5000 in blocking buffer, and incubated for 1 h at RT. Following the addition of developing washes, 100 µL of ABcam (Abcam) was added to each well and the absorbance at 650 nm was read after 20 min (BioTek 800 TS).

Antibody inhibition of hACE2 binding to cell-expressed spike. Expi293F cells were transfected with pcDNA 3.1 containing S bearing wild type, Alpha, Beta, or Delta variants, using the ExpiFectamine 293 Transfection Kit (Thermo Fisher). The following day, the harvested, centrifuged, and pelleted cells were resuspended in FACS buffer (PBS ± x1, 2% FBS and 2 mM EDTA). Next, 2 × 10⁶ cells were aliquoted into a 24-well plate (Corning), so that each well contained 3 × 10⁶ cells in 1 mL of FACS buffer. TAU antibodies or mGO53 were added to the appropriate wells at a ratio of 1:2:1, respectively, according to the manufacturer’s instructions. The supernatant was harvested by centrifugation at 300 × g, and the resultant cell supernatant by using StrepTactin resin (IBA). The eluted material was further purified by size-exclusion chromatography with a Superdex 200 Increase 10/300 column (GE Healthcare) running in a buffer containing 20 mM HEPES pH 8.0 and 150 mM NaCl.

Vero-TMPRSS2 or Calu-3 cells were infected as above and 100 µL of reservoir virus stock. The viruses were then used to infect Hi5 cells for RBD expression. Secreted RBD in the supernatant was harvested and applied to cobalt agarose beads, then eluted with 300 mM imidazole, and further purified by using a Superdex 200 Increase 10/300 column (GE Healthcare) running in a buffer containing 20 mM HEPES at pH 8.0 and 150 mM NaCl.

Immuno-fluorescence imaging and analysis. For viral nucleocapsid detection in Vero-TMPRSS2 cells by immunofluorescence, cells were washed twice with PBS ± x1 and fixed in 4% formaldehyde for 30 min at RT. Fixed cells were washed with PBS ± x1 and permeabilized for immunofluorescence using BD Cytofix/Cytopermen according to manufacturer’s protocol. The nuclei were counterstained with 1 µM Sytox Green, infected cells from whole wells were imaged on the Incucyte S3 (Sartorius). Data were logged from the Incucyte analysis modules and graphed with GraphPad Prism 8.

Results

Expression and purification of soluble RBD, spike and antibodies for crystallization. SARS-CoV-2 RBD residues Arg319 to Lys529 was expressed by using the Bac-to-Bac Baculovirus System (Invitrogen). RBD containing the gp67 signal peptide and a C-terminal 6×His tag was inserted into pFastBac1 to form the plasmid pFastBac1-RBD. The plasmid was then transformed into DH10 Bac component cells. The recombinant bacmid was extracted and further transformed into E. coli BL21 (DE3) containing the pETDuet-1 vector harboring a T7 RNA polymerase expression cassette. The rbcS promoter, which is induced by a strain for SARS-CoV-2, was used to transcribe and amplify the T7 RNA polymerase gene, and then for inducible expression of a primary nucleocapsid antibody (1 µg/mL) (GeneTex GTX133537) and a secondary anti-rabbit AF594 antibody (ThermoFisher, A11037). The nuclei were counterstained with 1 µM Sytox Green. Infected cells from whole wells were imaged using the Incucyte 3S (Sartorius). Data were logged from the Incucyte analysis modules and graphed with GraphPad Prism 8.

Immunofluorescence imaging and analysis. For viral nucleocapsid detection in Vero-TMPRSS2 cells by immunofluorescence, cells were washed twice with PBS ± x1 and fixed in 4% formaldehyde for 30 min at RT. Fixed cells were washed with PBS ± x1 and permeabilized for immunofluorescence using BD Cytofix/Cytopermen according to manufacturer’s protocol. The nuclei were counterstained with 1 µM Sytox Green, infected cells from whole wells were imaged on the Incucyte S3 (Sartorius). Data were logged from the Incucyte analysis modules and graphed with GraphPad Prism 8.

Vero-TMPRSS2 cells were infected with SARS-CoV-2 nucleocapsid (1 µg/mL) TCID₅₀ was calculated using the Reed-Muench method49–51.

Vero-TMPRSS2 cells were infected with nucleocapsid (1 µg/mL) TCID₅₀ was calculated using the Reed-Muench method49–51.

Vero-TMPRSS2 cells were infected with nucleocapsid (1 µg/mL) TCID₅₀ was calculated using the Reed-Muench method49–51.
solution containing 0.2 M sodium tartrate dibasic dihydrate and 14% (w/v) polyethylene glycol 3350. Crystals were soaked in the reservoir solution supplemented with 1 M ammonium sulfate and flash-frozen in liquid nitrogen for data collection.

The Fab portion of TAU-2212 was concentrated to 7 mg/mL for crystallization. The Fab portion of TAU-2212 was concentrated to 7 mg/mL for crystallization. The Fab portion of TAU-2212 was concentrated to 7 mg/mL for crystallization. The Fab portion of TAU-2212 was concentrated to 7 mg/mL for crystallization. The Fab portion of TAU-2212 was concentrated to 7 mg/mL for crystallization.

Data collection, structure determination, and refinement. The X-ray diffraction data were collected at the beamlines BL18U (RBD-Fab2303) and BL10U1 (Fab2212) of the Shanghai Synchrotron Research Facility. The wavelength was 0.980 Å and the data collection temperature was 100 K. Data were processed and scaled with HKL2000.

The structure determination was performed using PHASER. Manual building and adjustments of the structures were performed in COOT. The refinement of the structures was performed using PHENIX. A total of 96,230 particles were selected for the initial model refinement using PHENIX. Data processing showed that the crystal of Fab2212 belongs to the space group P61.

However, the merohedral twinning appears to assign the crystal to the space group P62,22. The structure of Fab2212 was refined against the twinned data by using Relmack55 with the twinning operator k, h, -l and an estimated initial twin ratio of 0.60 to 0.40. Data collection and refinement statistics are listed in Table 1. The Ramachandran statistics are as follows: 97.24% favored and 2.76% disallowed.

The crystal was grown at 16 °C in 26% (w/v) polyethylene glycol 3350, 0.2 M (NH4)2SO4, pH 8.0. Crystals were soaked in the reservoir solution supplemented with 10% glycerol, and flash-frozen in liquid nitrogen for data collection.

Data availability

The atomic coordinates and EM maps have been deposited into the Protein Data Bank (http://www.pdb.org) and the EM Data Bank, respectively: Fab2303–RBD complex (PDB: 7WVW); Fab2303-S complex (EMD: 32411), Fab2212–PDB: 7WC0), mAb2212–S complex in conformation 1 (EMD: 32416), conformation 2 (EMD: 32417), conformation 3 (EMD: 32418), conformation 4 (EMD: 32421), conformation 5 with single spike (EMD: 32419).

Received: 17 February 2022; Accepted: 18 July 2022; Published online: 05 August 2022

References

1. Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2523 (2021).
2. Lucas, C. et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature https://doi.org/10.1038/s41586-021-04085-y (2021).
3. Bates, T. A. et al. Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. Nat. Commun. 12, 5135 (2021).
4. Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643–650 (2020).
5. Kesar, S. et al. Longitudinal isolation of Potent Near-Germline SARS-CoV-2 Neutralizing Antibodies from COVID-19 Patients. Cell 182, 843–854 e812 (2020).
6. Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature https://doi.org/10.1038/s41586-020-2456-9 (2020).
7. Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science https://doi.org/10.1126/science.abc7520 (2020).
8. Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science https://doi.org/10.1126/science.abd7424 (2020).
9. Mor, M. et al. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. PLoS Pathog. 17, e1009165 (2021).
10. Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010–1014 (2020).
11. Pitzalis, M. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014–1018 (2020).
12. Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19. N. Engl. J. Med. 384, 229–237 (2021).
13. Chen, R. E. et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature 596, 103–108 (2021).
14. Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021).
15. Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384–2393 e2312 (2021).
16. Copin, R. et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell 184, 389–396.e391 (2021).

17. Rambaut, A. et al. Preliminary Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in the UK Defined by a Novel Set of Spike Mutations. https://virology.org/ (preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/2021/03/08).

18. Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438–443 (2021).

19. Faria, N. R. et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. J. Virol. https://doi.org/10.1128/JVI.00119-21 (2021).

20. Mikolova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature https://doi.org/10.1038/s41586-021-03994-y (2021).

21. Edara, V. et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617.2 Variants. N. Engl. J. Med. 385, 664–666 (2021).

22. Gowrisankar, A., Priyanka, T. M. C., & Banerjee, S. Omicron: a mysterious variant of concern. Eur. Phys. J. 137, 100 (2022).

23. Deng, X. et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 184, 3426–3437.e3428 (2021).

24. Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 Spike protein variants. Elife https://doi.org/10.7554/elifesc.61312 (2020).

25. Thomson, E. C. et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell 184, 1171–1187.e1120 (2021).

26. Fonager, J. et al. Working Paper on SARS-CoV-2 Spike Mutations Arising in Danish Mink, Their Spread to Humans and Neutralization Data. https://files.ssi.dk/Mink-cluster-5-short-report_AF02 (2020).

27. ECDC. https://doi.org/10.2801/10025510.10.1016/j.xcrm.2021.100255 (2021).

28. Mansbach, R. A. et al. The SARS-CoV-2 Spike variant D614G favors an open conformation of the receptor-binding domain. J. Virol. 94, e01377-20 (2021).

29. Greaney, A. J. et al. Mapping mutations to the SARS-CoV-2 RBD that escape the monoclonal antibody LY-CoV016. Cell 184, 1284–1300.e1294 (2021).

30. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126–2132 (2004).

31. Adams, P. D. et al. PHENIX: a comprehensive Python-based system formacromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213–221 (2020).

32. Murashov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D. Biol. Crystallogr. 67, 355–367 (2011).

33. Collaborative Computational Project, N. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D. Biol. Crystallogr. 50, 760–763 (1994).

34. Potters, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).

35. Goddard, T. D. et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018).

36. Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).

37. Zhang, K. GetFF: Real-time CTF determination and correction. J. Struct. Biol. 193, 1–12 (2016).

38. Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife https://doi.org/10.7554/elifesc.61286 (2018).

39. Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 183, 1735 (2020).

40. Liu, L. H. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450 (2020).

41. van Heel, M. & Schatz, M. Fourier shell correlation threshold criteria. J. Struct. Biol. 151, 250–262 (2005).

42. Scheres, S. H. W. & Chen, S. X. Prevention of overfitting in cryo-EM structure determination. Nat. Methods 9, 853–854 (2012).

43. Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374–1377 (2003).

Acknowledgements

We thank the members of the Xiang and Freund labs for fruitful discussions and assistance. We thank Noam Ben-Shalom and the Blavatnik Center for Drug Discovery at Tel Aviv University for help with PCR measurements. NTF is funded by the ISF grant number #1422/18. MGT and NTF are funded by KillCorona ISF grant number #3711/20. XYL is funded by the Spring Breeze Fund of Tsinghua University, the National Natural Science Foundation of China (grants: 31925023, 3186143027), the Ministry of Science and Technology of China (grant 2021YFA1300200), the Beijing Frontier Research Center for Biological Structure, and the Beijing Advanced Innovation Center for Structure Biology. AFC is supported by NIH grant (K99 AI130381) and AFC is supported by Career Award for Medical Scientists from the Burroughs Wellcome Fund. MD is funded by the BARDF grant #5-S270-20R and ISF grant #401/18. BAC is supported by a United States-Israel Binational Science Foundation grant. The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281. The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/SouthAfrica/KRISP-K005325/2020, NR-54009, contributed by Alex Sigal and Tulio de Oliveira. The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/Iran/T3/5/2021 (Brazili P.1), NR-59482, supported by National Institute of Allergy and Infectious Diseases. The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/USA/PCH658/2021 (Lineage B.1.617.2; Delta Variant), NR-55611, contributed by Dr. Richard Webby and Dr. Anami Patel. We thank Dr. Louise Laurent for providing the B.1.1.7 clinical sample (Lineage B.1.617.2; Delta Variant), NR-55611, contributed by Dr. Richard Webby and Dr. Anami Patel. We thank Dr. Louise Laurent for providing the B.1.1.7 clinical sample (Lineage B.1.617.2; Delta Variant), NR-55611, contributed by Dr. Richard Webby and Dr. Anami Patel.

14 COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-022-03739-5 | www.nature.com/commsbio
Author contributions
M.M. planned and performed the biochemical experiments, analysed data, prepared the figures, and wrote the manuscript together with N.T.F., Y.X., and B.A.C. R.L. and B.M. performed crystal and cryoEM structure determination and analysis, prepared the figures, and wrote the manuscript together with N.T.F., Y.X., and B.A.C. M.W., J.A., M.D. and M.G.T. performed the pseudo-viral assays. J.C.L. performed cell line maintenance and plate setup for BSL-3 assays. A.E.C. and A.F.C. conducted virus generation and titrating. S.L.L. and B.A.C. designed and performed BSL-3 assays. Y.X., N.T.F., and B.A.C. planned and supervised the experiments, analyzed the data and wrote the manuscript.

Competing interests
The authors declare no competing interests.

Ethics statement
All the authors meet the authorship criteria, and gave their consent to be listed as authors on this manuscript.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s42003-022-03739-5.

Correspondence and requests for materials should be addressed to Ben A. Croker, Ye Xiang or Natalia T. Freund.

Peer review information Communications Biology thanks Elisa Fadda, Alex Cohen and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editors: Isabelle Lucet and Gene Chong. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022